3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Breast Neoplasms
39
Neoplasms
37
Depression
29
Prostatic Neoplasms
23
Fatigue
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Multiple Myeloma
15
Lymphoma, Follicular
15
Lymphoma, Large B-Cell, Diffuse
13
Carcinoma, Non-Small-Cell Lung
13
Anxiety Disorders
13
Lymphoma, Mantle-Cell
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Burkitt Lymphoma
12
Pain
11
Lymphoma, Non-Hodgkin
11
Lymphoma, B-Cell, Marginal Zone
11
Lung Neoplasms
11
Lymphoma, Large-Cell, Immunoblastic
10
Leukemia, Myeloid, Acute
10
Colorectal Neoplasms
10
Leukemia, Myeloid, Chronic-Phase
9
Hodgkin Disease
9
Blast Crisis
9
Vomiting
8
Nausea
8
Lymphoma
8
Leukemia, Myeloid, Accelerated Phase
8
Head and Neck Neoplasms
8
Uterine Cervical Neoplasms
7
Interventions
Cholecalciferol
4
Nutrition Assessment
3
Exercise
3
Blood Pressure
3
Atorvastatin
3
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
Vitamin E
2
Vitamin D
2
Rosuvastatin Calcium
2
Methods
2
Metformin
2
Gonadotropin-Releasing Hormone
2
Geritol
2
Fish Oils
2
Fatty Acids, Omega-3
2
Ethanol
2
Educational Status
2
Diet, Mediterranean
2
Aspirin
2
xinmailong
1
sofosbuvir-velpatasvir drug combination
1
pembrolizumab
1
palbociclib
1
ficlatuzumab
1
beta Carotene
1
amlodipine, atorvastatin drug combination
1
Vorinostat
1
Vitamin B 6
1
Vitamin B 12
1
Tumor Necrosis Factor Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cardiovascular Diseases
×
Therapeutics
×
Clear all
NCT03443635
2022-04-29
CHOP
Tulane University
Phase 1/2
Completed
7,192 enrolled
7 charts